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Abstract The antineoplastic alkyl lysophospholipids (ALP) 
l-0-octadecyl-2-0-methyl-rac-grycero-3-phosphocholine (ET-
I8-OCH3) and l-S-hexadecylthio-2-methoxymethyl-2-deoxy-
rac-glycero-3-phosphocholine (BM 41.440) were found to alter 
phospholipase D (PLD)-mediated phosphatidylcholine (PtdCho) 
and phosphatidylethanolamine (PtdEtn) hydrolysis in NIH3T3 
fibroblasts. After a shorter (50 min) treatment, 2.5-7.5 H-g/ml 
concentrations of ALP stimulated PtdCho, but not PtdEtn, 
hydrolysis 2^4-fold. At the same time, 7.5-25 (ig/ml concentra-
tions of ALP significantly inhibited the larger (5.8-6.5-fold) 
stimulatory effects of phorbol 12-myristate 13-acetate (PMA) on 
both PtdCho and PtdEtn hydrolysis. When a brief (30 min) 
exposure of cells to 1-2.5 iig/ml concentrations of BM 41.440 
was followed by incubation of washed cells for 3-16 h prior to the 
assay of PLD activity or DNA synthesis, the treated cells 
exhibited no increased PtdCho hydrolysis, while their responses 
to the stimulatory PMA effects on both PLD activity and DNA 
synthesis were strongly reduced. The results suggest that the 
PLD and protein kinase C systems may be important cellular 
targets of ALP actions. 
© 1997 Federation of European Biochemical Societies. 
1. Introduction 
The alkyl lysophospholipids (ALP) 1-0-octadecy 1-2-0-
methyl-rac-glycero-3-phosphocholine (ET-I8-OCH3) and \-S-
hexadecylthio-2-methoxymethyl-2-deoxy-rac-glycero-3-phos-
phocholine (BM 41.440) represent prototypes of anti- tumor 
ether lysophospholipids [1^4-]. A L P do not directly affect 
D N A synthesis and their most likely target is the plasma 
membrane. Accordingly, A L P have been shown to inhibit 
several important membrane-associated activities, including 
de novo phosphatidylcholine (PtdCho) synthesis [5], 
N a + , K + - A T P - a s e and sodium pump activity [6,7], epidermal 
growth factor binding [8], arachidonate release by phospholi-
pase A2 [9], phosphatidylinositol-specific phospholipase C ac-
tivity [10], as well as calcium signaling [11]. A L P also inhibit 
the activities of phosphatidylinositol-3'-kinase [12] and p42/ 
p44 mitogen activated kinases [13], but they stimulate expres-
sion of fos and jun proto-oncogenes [14]. 
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A L P have also been found to inhibit protein kinase C 
(PKC) activity in vitro through competitive inhibition of 
phosphatidylserine binding to the regulatory domain of calci-
um-dependent P K C isozymes [15,16], and to inhibit phorbol 
12-myristate 13-acetate (PMA)-induced protein phosphoryla-
tion in intact HL60 cells [17]. However, the biological signifi-
cance of P K C inhibition by A L P is presently unclear. 
Major targets of the P M A activated P K C system includes 
phospholipase D (PLD) acting on P tdCho [18-22] and/or 
phosphatidylethanolamine (PtdEtn) [23]. Since some of the 
primary and secondary products of P tdCho and PtdEtn hy-
drolysis, including phosphatidic acid, 1,2-diacylglycerol, etha-
nolamine and phosphocholine, can regulate cell growth [re-
viewed in ref. [24]], it was of interest to determine the effects 
of A L P on the hydrolysis of these phospholipids. 
In the present study, we have therefore examined the effects 
of ET-18-OCH 3 and BM 41.440 on PLD-mediated phospho-
lipid hydrolysis in N I H 3T3 fibroblasts which express both the 
P tdCho- and PtdEtn- hydrolyzing P L D activities [25]. Our 
data show that A L P exert multiple, previously unrecognized, 
effects on PLD-mediated phospholipid hydrolysis, including 
transient stimulation of a PtdCho-specific P L D activity and 
lasting inhibition of PMA-stimulated hydrolysis of both 
PtdCho and PtdEtn. 
2. Materials and methods 
2.1. Materials 
BM41.440 (Ilmofosine) was a generous gift from Dr. Dieter B.J. 
Herrmann, Boehringer Mannheim GmbH (Mannheim, Germany). 
ET-I8-OCH3 was either purchased from Bachem Feinchemikalien 
(Bubendorf, Switzerland) or was provided by Dr. Wolfgang J. Bau-
mann (The Hormel Institute, Austin, MN). Both compounds were 
more than 99% pure as determined by thin layer chromatography 
and carbon-13 NMR. PMA, phosphocholine, sphingosine-1-phos-
phate and Dowex-50W[H+] were purchased from Sigma; insulin 
was from Boehringer Mannheim. [l-14C]Palmitic acid (60 mCi/ 
mmol), [methyl-]iC]cho\me chloride (50 mCi/mmol) and [2-14C]-
ethanolamine (50 mCi/mmol) were bought from Amersham. Phospha-
tidylethanol (PtdEtOH) was from Avanti Polar Lipids. Tissue culture 
reagents were purchased from Gibco BRL. 
2.2. Cell culture 
NIH3T3 clone-7 fibroblasts were obtained from Dr. Douglas R. 
Lowy (National Cancer Institute, NIH, Bethesda, MD) and main-
tained in Dulbecco's modified Eagle's medium (DMEM) as described 
previously [26]. 
2.3. Measurement of PtdEtOH formation 
NIH3T3 cells were grown in 12-well plates in the presence of 
[l-14C]palmitic acid (1 uCi/ml) and 10% fetal calf serum for 24 h. 
The cultures were washed and incubated in fresh serum-containing 
medium for 2 h to decrease the amount of unesterified radiolabeled 
palmitic acid. Finally, the medium was replaced by serum-free me-
dium, and incubations were continued in the presence of 150 mM 
ethanol for 50 min. ALP were present throughout the incubation, 
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while PMA was added 20 min after the start of incubation. Incuba-
tions were terminated by scraping the cells into 2 ml of ice-cold meth-
anol, followed by rapid transfer of the methanol extract into 2 ml of 
chloroform. After phase separation, PtdEtOH present in the chloro-
form layer was separated from other phospholipids on potassium 
oxalate (l%)-impregnated Silica Gel H plates (Analtech) with chloro-
form/methanol/acetone/acetic acid/water (50:10:15:10:2, by vol) as 
developing solvent. 
2.4. Determination of PLD-mediated formation of [uC]choline and 
[14 CJethanolamine from prelabeled phospholipids 
For these experiments, attached NIH3T3 cells (grown in 12-well 
plates) were labeled for 48 h with [14C]choline (1 uCi/ml) or 
[14C]ethanolamine (0.75 uCi/ml). The cells were washed, incubated 
in serum-free medium for 2 h, washed again, and finally treated 
with ALP and/or PMA in serum free-medium supplemented with 
20 mM choline or 2 mM ethanolamine, as applicable. Supplementa-
tion with unlabeled choline and ethanolamine suppressed further me-
tabolism of newly formed radiolabeled choline and ethanolamine 
[25,27]. Incubations with ALP were carried out for 50 min; when 
applicable, PMA was added to the cells 20 min after the start of 
incubation. In other experiments, prelabeled cells were treated first 
with 1-2.5 |Xg concentrations of BM41.440 for 30 min, washed, and 
then incubated for 3 h in the absence of BM 41.440. Cells were washed 
again, and then incubated in fresh serum-free medium (containing 
20 mM choline or 2 mM ethanolamine, as appropriate) for 50 min 
in the absence or presence of PMA. In each case, incubations were 
terminated by adding to the cell cultures 2 ml of ice-cold methanol. 
Then, the cells were scraped into methanol, and the methanol extract 
was rapidly transferred into 2 ml of chloroform. After phase separa-
tion, radiolabeled choline and ethanolamine were separated on Dow-
ex-50W[H+]-packed columns (Bio-Rad Econo columns; 0.75 ml bed 
volume) using the procedure described by Cook and Wakelam [28] 
with minor modifications. The initial flow-through (4.5 ml) along with 
a following 5 or 3.5 ml wash contained glycerophosphocholine and 
glycerophosphoethanolamine, respectively. Phosphocholine and phos-
phoethanolamine were eluted by 18 and 15 ml of water, respectively. 
Finally, choline and ethanolamine were eluted by 12.5 and 10 ml of 
1 M HC1, respectively. The metabolites of radiolabeled choline and 
ethanolamine were further identified by TLC, and phospholipids were 
separated as previously described [25]. 
2.5. Labeling of cellular DNA with [3 H']'thymidine 
NIH3T3 cells were grown in 12-well tissue culture plates in the 
presence of 10% serum to about 40% confluency, washed, and then 
incubated in serum-free medium for 24 h. Cell cultures (~70-80% 
confluent) were treated with 1-2.5 ug/ml concentrations of BM41.440 
for 30 min, washed, and then treated (in serum-free medium) for 16 h 
with PMA, insulin, phosphocholine, or sphingosine-1-phosphate as 
indicated in Fig. 4. After treatments, incubations were continued in 
the presence of [me;/!j;/-3H]thymidine (1 uCi/well) for 60 min. The 
cells were first washed twice with phosphate-buffered saline, then 
4 times with 5% trichloroacetic acid, and finally twice with absolute 
ethanol. The acid-insoluble material was dissolved in 0.3 M sodium 
hydroxide, and an aliquot was taken to measure DNA-associated 3H 
activity in a liquid scintillation counter. 
3. Results and discussion 
Treatment of NIH3T3 cells with 2.5-25 ug/ml concentra-
tions of ET-I8-OCH3 or BM41.440 for 50 min in serum-free 
medium did not result in detectable changes in the number of 
trypan blue excluding cells, as determined immediately after 
the treatments. However, when cells were treated with 2.5, 10 
and 25 Ug/ml concentrations of ALP for 30 min and then the 
ratio of viable and healthy cells was determined 18 h later, 0, 
30^40 and 100% of cells were dead, respectively. In agreement 
with an earlier report [10], these data indicate that NIH 3T3 
cells are moderately sensitive to the cytotoxic actions of ALP. 
Based on these data, we limited the highest concentration of 
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Fig. 1. Effects of ALP on PtdCho and PtdEtn hydrolysis in NIH fibroblasts. NIH3T3 fibroblasts were labeled with [14C]choline (A) or 
[14C]ethanolamine (B) for 48 h, followed by treatments with ET-I8-OCH3 (O-*) or BM41.440 ( A - A ) at the indicated concentrations for 
50 min; 100 nM PMA was absent (open symbols) or present (closed symbols) during the last 30 min of incubation. Each data point represents 
the mean ± S.E.M. of three individual experiments in triplicate. 
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Fig. 2. Effects of ALP on [14C]PtdEtOH formation in NIH3T3 fi-
broblasts. [14C]Palmitic acid-labeled NIH3T3 fibroblasts incubated 
in the presence of 150 mM ethanol were left untreated (open bars) 
or treated with 25 ug/ml of ET-I8-OCH3 (cross-hatched bars) or 
25 ug/ml of BM 41.440 (filled bars) for 50 min; 100 nM PMA was 
absent (I) or present (II) during the last 30 min of incubation. Data 
represent the mean ± S.E.M. of three independent experiments in 
triplicate. Significance of differences from the untreated control (*) 
or from the effect of PMA alone (**) is indicated by asterisks 
(P< 0.05-0.01; Student's t test). 
ALP to 25 and 2.5 (ig/ml in the shorter-term (50 min) and 
longer-term (3-16 h) experiments, respectively. 
Within the 2.5-25 ug/ml concentration range, both ET-18-
OCH3 and BM 41.440 stimulated the formation of 
[14C]choline from [14C]PtdCho when incubations were carried 
out in serum-free medium for 50 min. Nearly maximal (2.6-
3.4-fold) and maximal (2.9-3.7-fold) stimulatory effects were 
observed with 7.5 and 15 ug/ml concentrations of ALP, re-
spectively (Fig. 1 A). In contrast, neither of the ALP enhanced 
the formation of [14C]ethanolamine from [14C]PtdEtn (Fig. 
IB). 
In agreement with our previous finding [25], in NIH3T3 
cells the PMA-activated PLD system hydrolyzed significant 
amounts of both PtdCho (Fig. 1A) and PtdEtn (Fig. IB). 
Both alkyl lysophospholipid analogues inhibited PMA-in-
duced hydrolysis of [14C]PtdCho (Fig. 1A) and [14C]PtdEtn 
(Fig. IB). However, in the case of PtdCho even a high con-
centration (25 |J.g/ml) of ALP incompletely inhibited the large 
stimulatory effect of PMA, reflecting the stimulatory effects of 
ALP in the absence of PMA (Fig. 1A). By contrast, ALP 
potently inhibited the stimulatory effects of PMA on PtdEtn 
hydrolysis (Fig. IB). 
It has been shown that ALP are biologically more active 
when added to cells in serum-free medium [29]. We also found 
that in the presence of 10% serum both the stimulatory and 
inhibitory effects required about 3-times higher concentrations 
of ALP (data not shown). To facilitate data comparisons with 
literature data, we continued to use serum-free medium for 
the following studies. 
[14C]Palmitic acid-labeled cells are suitable to demonstrate 
activation of PLD activity, although this method does not 
allow separate analysis of PtdCho and PtdEtn hydrolysis 
[23]. After equilibrium labeling of cells with radiolabeled pal-
mitic acid, the ratio of 14C-activity in PtdCho and PtdEtn, on 
a molar basis, is roughly 2:1. Considering that PtdEtn is sig-
nificantly labeled with this fatty acid, that its hydrolysis is not 
stimulated by ALP, and that in unstimulated cells more 
PtdEtn than PtdCho is degraded, it was expected that ALP 
would have smaller stimulatory effects on [14C]PtdEtOH for-
mation (through the transphosphatidylation reaction) than on 
[14C]choline formation. Indeed, as shown in Fig. 2, ET-
I8-OCH3 and BM 41.440 (25 ug/ml, each) enhanced 
[14C]PtdEtOH formation 1.8-1.9-fold, which is about half 
the rate of stimulation observed in case of PtdCho hydrolysis. 
Nevertheless, these experiments indicated that increased for-
mation of [14C]choline from [14C]PtdCho in ALP-treated fi-
broblasts was catalyzed by a PLD activity. 
PMA-induced PtdEtOH formation was more effectively in-
hibited by ALP (Fig. 2) than PMA-induced PtdCho hydrol-
ysis (Fig. 1A). The reason for this discrepancy is that PMA-
induced PtdEtn hydrolysis is more strongly inhibited by ALP 
than PtdCho hydrolysis, and that PtdEtn also is a substrate 
for PtdEtOH formation. 
Subsequent experiments revealed that the cells can be sen-
sitized to the inhibitory effects of ALP by including a longer 
incubation time between initial ALP treatment and the fol-
lowing PMA treatment. Thus, when [14C]choline- or 
[14C]ethanolamine-prelabeled cells were treated with 1-2.5 
ug/ml concentrations of BM 41.440 for only 30 min and 
then incubated for a 3 h period prior to treatments with 
PMA, BM 41.440 considerably inhibited, particularly at the 
higher (2.5 ug/ml) concentration, PMA-induced hydrolysis 
of both PtdCho (Fig. 3A) and PtdEtn (Fig. 3B). In the 
same experiment BM 41.440 did not stimulate PtdCho hydrol-
ysis in the absence of PMA (Fig. 1A). 
The role of PLD in the mediation of mitogenic effects of 
PMA and growth factors has not been clarified yet. The 
emerging view is that PLD activation is one of the important 
early cellular responses induced by mitogens, which must be 
followed by other signals for the mitogenesis to proceed [30-
32]. In this context, it was of interest to determine how ALP 
affect mitogenesis induced by PMA and other regulatory 
agents such as insulin alone or phosphocholine plus sphingo-
sine-1-phosphate in combination. Previously, all these agents 
were shown to stimulate DNA synthesis in NIH3T3 cells [33]. 
As shown in Fig. 4, 1 ug/ml of BM 41.440 had no significant 
effect on insulin- or phosphocholine plus sphingosine-1-phos-
phate-induced DNA synthesis, while it inhibited the mitogenic 
effect of PMA by 70%. At a 2.5 ug/ml concentration 
BM 41.440 still had no significant effect on insulin-induced 
DNA synthesis and only modestly (-40%) inhibited the com-
bined effects of phosphocholine and sphingosine-1-phosphate, 
while it practically abolished the stimulatory effect of PMA 
(Fig. 4). In another experiment, 2.5 ug/ml of BM 41.440 in-
hibited the mitogenic effect of 10% serum only by about 20%. 
These experiments suggest that ALP primarily affects mito-
genesis regulated by the PKC system, while the effects of other 
mitogens are less sensitive to the inhibitory action of ALP. 
In conclusion, we have shown that the alkyl lysophospho-
lipids examined here can exert transient stimulatory effects on 
PLD-mediated PtdCho hydrolysis as well as lasting inhibitory 
effects on PMA-induced phospholipid hydrolysis and DNA 
316 Z. Kiss, K.S. CrillylFEBS Letters 412 (1997) 313-317 
"E 
o 
£ o ° 
£ I 
o _gj 
o c 
CO 
o 
0 
Q. 
CO 
O .c 
Q . 
O 
■S^ L E 
03 Q_ 
.? «° O 
£ 
Q. 
■o 
n n 
Fig. 3. Effects of BM41.440 on PtdCho and PtdEtn hydrolysis determined after a 3 h lag period following treatments with BM41.440. 
NIH 3T3 fibroblasts were labeled with [14C]choline (A) or [14C]ethanolamine (B) for 48 h. Cells were washed and then incubated in serum-free 
medium for 30 min in the absence (open bars) or presence of 1 ug/ml (cross-hatched bars) or 2.5 ug/ml (filled bars) of BM 41.440. Cells were 
washed and then incubated for 3 h in fresh serum-free medium. Finally, cells were washed again and then incubated (in serum-free medium 
containing either 20 mM choline or 2 mM ethanolamine as appropriate)) for 50 min in the absence (I) or presence (II) of 100 nM PMA. Data 
represent the mean ± SD (n = 4) in a single experiment representative of three. 
synthesis. Prolonged incubation of ALP-treated cells was 
found to increase the inhibitory potency of ALP. This would 
be consistent with the mediation of inhibitory ALP effects by 
a metabolite formed from ALP. Indeed, l-O-hexadecyl-2-ace-
tyl-sn-glycerol, which is known to be formed by PLC-medi-
ated hydrolysis of ET-I8-OCH3, was shown to be a potent 
inhibitor of PKC [34-36]. We are presently investigating the 
possibility that NIH 3T3 cells are also able to form a similar 
PKC inhibitor from BM 41.440. Alternatively, time-dependent 
redistribution of ALP to intracellular membranes containing 
the PMA-inducable PLD activities could explain the lag peri-
Fig. 4. Effects of BM 41.440 on DNA synthesis induced by PMA 
and other mitogens. Serum-starved (24 h) NIH3T3 fibroblasts were 
incubated (in serum-free medium) for 30 min in the absence (open 
bars) or presence of 1 ug/ml (cross-hatched bars) or 2.5 ug/ml (filled 
bars) of BM 41.440. Cells were washed and then incubated (in se-
rum-free medium) for 16 h in the absence of other additions (I) or 
in the presence of 500 nM insulin (II), 1 mM phosphocholine plus 
1 uM sphingosine-1-phosphate (III), or 100 nM PMA. Data repre-
sent the mean±SD (n = 3) in a single experiment representative of 
three. 
n m m 
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od needed to enhance the inhibitory potency of ALP . P M A - [17 
induced mitogenesis was also preferentially inhibited by low 
concentrations of ALP. This is a further indication that the 
P K C system is likely to be one of the primary targets of ALP. [19 
It remains to be determined if and how the effects of ALP on 
the PLD and P K C systems relate to their antineoplastic ef- P ° 
fects. [ 2 1 
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